EXEL

44.47

0.47% 0.21

Vorhandelsmarkt: 44.47

Exelixis Inc (EXEL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EXEL? Forum Prognose

Schlusskurs vom Vortag:

$44.26

Offen:

$44.29

24-Stunden-Volumen:

2.28M

Relative Volume:

0.72

Marktkapitalisierung:

$12.13B

Einnahmen:

$2.17B

Nettoeinkommen (Verlust:

$521.27M

KGV:

25.12

EPS:

1.77

Netto-Cashflow:

$633.79M

1W Leistung:

+0.93%

1M Leistung:

+10.16%

6M Leistung:

+35.25%

1J Leistung:

+96.77%

1-Tages-Spanne:

$43.86

$44.84

1-Wochen-Bereich:

$43.86

$45.52

52-Wochen-Spanne:

$22.20

$49.62

Exelixis Inc Stock (EXEL) Company Profile

Firmenname

Exelixis Inc

Sektor

Healthcare (1161)

Branche

Biotechnology (653)

Telefon

(650) 837-7000

Adresse

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Mitarbeiter

1,147

Twitter

@exelixisinc

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

EXEL's Discussions on Twitter

Vergleichen Sie EXEL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EXEL Exelixis Inc	44.47	12.02B	2.17B	521.27M	633.79M	1.77
VRTX Vertex Pharmaceuticals Inc	470.13	119.21B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	560.93	59.16B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	325.28	40.57B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	571.23	34.02B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	295.59	29.19B	3.81B	-644.79M	-669.77M	-6.24

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-08	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-06-24	Hochstufung	Stephens	Equal-Weight → Overweight
2025-02-24	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2025-01-24	Herabstufung	Oppenheimer	Outperform → Perform
2024-12-20	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-12-17	Herabstufung	BofA Securities	Buy → Neutral
2024-10-16	Bestätigt	RBC Capital Mkts	Outperform
2024-09-19	Eingeleitet	UBS	Neutral
2024-04-11	Herabstufung	Barclays	Overweight → Equal Weight
2023-12-19	Eingeleitet	BTIG Research	Buy
2023-12-15	Eingeleitet	Citigroup	Buy
2023-09-26	Eingeleitet	H.C. Wainwright	Buy
2023-08-22	Bestätigt	Oppenheimer	Outperform
2023-08-08	Eingeleitet	SVB Securities	Market Perform
2023-07-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2023-05-10	Fortgesetzt	Piper Sandler	Overweight
2023-03-09	Eingeleitet	Wells Fargo	Overweight
2023-01-26	Eingeleitet	Credit Suisse	Outperform
2022-10-18	Eingeleitet	JMP Securities	Mkt Outperform
2022-06-24	Eingeleitet	BMO Capital Markets	Outperform
2021-11-19	Eingeleitet	Piper Sandler	Overweight
2021-11-03	Fortgesetzt	Jefferies	Buy
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Bestätigt	H.C. Wainwright	Buy
2021-06-15	Eingeleitet	H.C. Wainwright	Buy
2021-05-18	Fortgesetzt	Goldman	Sell
2021-03-31	Eingeleitet	Credit Suisse	Outperform
2021-03-12	Eingeleitet	Wolfe Research	Outperform
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Eingeleitet	SunTrust	Buy
2019-11-13	Eingeleitet	BofA/Merrill	Buy
2019-03-18	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-09-17	Eingeleitet	Goldman	Neutral
2018-09-10	Eingeleitet	Morgan Stanley	Underweight
2018-05-11	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	Needham	Buy
2017-10-17	Bestätigt	RBC Capital Mkts	Outperform
2017-10-16	Bestätigt	SunTrust	Buy
2017-09-22	Herabstufung	Leerink Partners	Outperform → Mkt Perform
2017-09-15	Eingeleitet	RBC Capital Mkts	Outperform
2017-09-12	Bestätigt	Needham	Buy
2017-07-14	Eingeleitet	SunTrust	Buy
2017-03-31	Eingeleitet	Needham	Buy
2017-03-16	Eingeleitet	Oppenheimer	Perform
2017-02-28	Herabstufung	Stifel	Buy → Hold
2016-11-03	Eingeleitet	Deutsche Bank	Buy
2016-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-09-15	Bestätigt	Stifel	Buy

Alle ansehen

Exelixis Inc Aktie (EXEL) Neueste Nachrichten

Jul 22, 2025

Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com

Jul 22, 2025

Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance

Jul 22, 2025

Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025

Jul 21, 2025

What analysts say about Exelixis Inc. stockStrong return on investment - Autocar Professional

Jul 21, 2025

Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance

Jul 21, 2025

Jul 20, 2025

Exelixis Inc. Stock Analysis and ForecastTremendous wealth creation - PrintWeekIndia

Jul 20, 2025

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - The Motley Fool

Jul 20, 2025

What drives Exelixis Inc. stock priceHigh-performance investment picks - jammulinksnews.com

Jul 20, 2025

Jul 18, 2025

Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest

Jul 18, 2025

Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail

Jul 18, 2025

Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa

Jul 18, 2025

Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com

Jul 18, 2025

Jul 16, 2025

Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st

Jul 16, 2025

Jul 15, 2025

Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com

Jul 15, 2025

Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance

Jul 15, 2025

Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail

Jul 15, 2025

Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada

Jul 15, 2025

Truist Lifts Price Target on Exelixis to $56 From $55, Keeps Buy Rating - MarketScreener

Jul 15, 2025

Jul 14, 2025

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - BioSpace

Jul 14, 2025

Press Release: Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025 - 富途牛牛

Jul 14, 2025

Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com

Jul 14, 2025

Exelixis’ Phase 3 Trial: A New Hope for Renal Cell Carcinoma? - TipRanks

Jul 14, 2025

Jul 12, 2025

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT) and Exelixis (EXEL) - The Globe and Mail

Jul 12, 2025

Jul 11, 2025

RBC Downgrades Exelixis to Sector Perform From Outperform, Lifts Price Target to $50 From $45 - MarketScreener

Jul 08, 2025

Exelixis (EXEL): Why Now is the Time to Act on Strong Clinical and Financial Catalysts - AInvest

Jul 08, 2025

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade) - Seeking Alpha

Jul 08, 2025

Jul 07, 2025

Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock? - The Globe and Mail

Jul 07, 2025

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance

Jul 07, 2025

Exelixis’s SWOT analysis: stock poised for growth amid pipeline progress - Investing.com

Jul 07, 2025

Jul 04, 2025

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy? - Yahoo Finance

Jul 04, 2025

Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025

Jul 02, 2025

Cancer index outperforms broader markets with 13% Q2 rebound - BioWorld MedTech

Jul 02, 2025

Jun 30, 2025